Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Elixiron Immunotherapeutics Inc.

Clinicaltrial registered29 Oct 2026

Elixiron Immunotherapeutics Inc.

29 Oct 2026: Trial registered · A Phase 1, Open-Label, Two-Stage, Food Effect Study to Assess the Safety, Tolerability, and Pharmacokinetics of EI-1071 Under Fasted or Fed Conditions in Healthy Volunteers. Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
29 Oct 2026
Title
A Phase 1, Open-Label, Two-Stage, Food Effect Study to Assess the Safety, Tolerability, and Pharmacokinetics of EI-1071 Under Fasted or Fed Conditions in Healthy Volunteers
Conditions
Food Effect in Healthy Volunteers
Phase
Phase 1
Study Type
Interventional
Status
Not Yet Recruiting
Countries
Taiwan
Country
Taiwan
Reference
NCT07903337
Location
Taiwan
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Elixiron Immunotherapeutics Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from Taiwan

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.